Sector
PharmaceuticalsOpen
₹253.8Prev. Close
₹259.45Turnover(Lac.)
₹5.66Day's High
₹269Day's Low
₹253.852 Week's High
₹30052 Week's Low
₹156.4Book Value
₹68.94Face Value
₹10Mkt Cap (₹ Cr.)
160.21P/E
87.14EPS
2.95Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 6.23 | 6.23 | 6.23 | 6.23 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 35.73 | 27.97 | 25.29 | 22.35 |
Net Worth | 41.96 | 34.2 | 31.52 | 28.58 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 50.86 | 54.25 | 43.79 | 40.79 |
yoy growth (%) | -6.24 | 23.88 | 7.34 | 14.99 |
Raw materials | -32.78 | -28.54 | -24.48 | -24.71 |
As % of sales | 64.44 | 52.62 | 55.9 | 60.59 |
Employee costs | -6.23 | -6.03 | -5.27 | -3.69 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 3.87 | 10.5 | 5.64 | 4.72 |
Depreciation | -1.01 | -1.03 | -1.02 | -0.93 |
Tax paid | -1.02 | -3.32 | -1.58 | -1.19 |
Working capital | 9.94 | 7.87 | 2.34 | 1.93 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -6.24 | 23.88 | 7.34 | 14.99 |
Op profit growth | -58.85 | 82.52 | -1.18 | 44.09 |
EBIT growth | -57.12 | 79.49 | 5.02 | 45.54 |
Net profit growth | -60.37 | 77.07 | 14.87 | 332.96 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.35 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493.2 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,483.15 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.4 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,167.95 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Sharat Deorah
Whole-time Director
Siddhartha Deorah
Independent Director
Kavita Vijayakant Sharma
Whole-time Director
Kiran Kulkarni
Independent Director
Vishal Kailash Chandra Jhunjhunwala
Independent Director
Mahendra Kumar Daga
Company Sec. & Compli. Officer
Priyanka Gupta
K-56 MIDC Indl Area,
Tarapur Boisar,
Maharashtra - 401506
Tel: 91-22-66635456
Website: http://www.aurolabs.com
Email: auro@aurolabs.com
9 ShivShakti Indl Es,
J R Boricha Marg, Lower Parel,
Mumbai - 400 011
Tel: 91-22-23016761/8261
Website: -
Email: -
Summary
Auro Laboratories Ltd, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API). Currently, the Company is specializing in producing Anti Diabetics like Me...
Read More
Reports by Auro Laboratories Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.